GO
Loading...

Roche CEO: InterMune perfect strategic fit

Monday, 25 Aug 2014 | 11:18 AM ET

CNBC's Meg Tirrell speaks to Roche CEO Severin Schwan, and InterMune CEO Daniel Welch, about Roche's $8.3 billion acquisition of InterMune and the opportunity for the drug Esbriet in the U.S.